Download Borstkanker en adjuvante therapie hebben invloed op de

‘Borstkanker en adjuvante therapie hebben invloed op de
seksualiteit Wat doet de bekkenbodem?’
Frida Barmentlo-Klein
geregistreerd bekkenfysiotherapeut in Huizen (Het Gooi)
Literatuur
1. Gommer AMPM. Cijfers borstkanker (prevalentie, incidentie en sterfte) Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid Bilthoven: RIVM;
2010. versie 4.0.
2. Borstkankervereniging Nederland. Hormoontherapie. Geraadpleegd op: 15 februari
2011. Beschikbaar via: www.borstkanker.nl/
hormoontherapie.
3. Broeckel JA, Thors CL, Jacobsen PB, Small
M, Cox CE. Sexual functioning in long-term
breast cancer survivors treated with adjuvant
chemotherapy. Breast Cancer Res Treat.
2002 Oct;75(3):241-8.
4. Punglia RS, Kuntz KM,Winer EP,Weeks JC,
Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant
endocrine therapy for postmenopausal
patients with early-stage breast cancer: a
decision analysis. Cancer. 2006 Jun
15;106(12):2576-82.
5. Morgan PA, Franks PJ, Moffatt CJ. Healthrelated quality of life with lymphoedema: a
review of the literature. Int Wound J. 2005
Mar;2(1):47-62.
6. Yang EJ, Kim SW, Heo CY, Lim JY. Longitudinal changes in sexual problems related to
cancer treatment in Korean breast cancer
survivors: a prospective cohort study. Support Care Cancer. 2010 Apr 25.
7. Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH. Menopausal-type symptoms in young breast cansurvivors.
Ann
Oncol.
2006
cer
Dec;17(12):1777-82.
8. Lunsen RH van, Laan E. Sex, hormones and
the brain. Eur J Contracept Reprod Health
Care. 1997 Dec;2(4):247-51.
9. Laan E, Lunsen RH van. Hormones and
sexuality in postmenopausal women: a
psychophysiological study. J Psychosom
Obstet Gynaecol. 1997 Jun;18(2):126-33.
10. Both S, Laan E, Schultz WW. Disorders in
sexual desire and sexual arousal in women, a
2010 state of the art. J Psychosom Obstet
Gynaecol. 2010 Dec;31(4):207-18.
11. Derzko C, Elliott S, Lam W. Management of
sexual dysfunction in postmenopausal breast
cancer patients taking adjuvant aromatase
inhibitor therapy. Curr Oncol. 2007 Dec;14
Suppl 1:S20-40.
12. Bolle G. Seksualiteitsbeleving na borstkankerdiagnose en behandeling. Tijdschrift voor
Seksuologie. 2002;26:131-7.
13. Basson R, Brotto LA, Laan E, Redmond G,
Utian WH. Assessment and management of
women's sexual dysfunctions: problematic
desire and arousal. J Sex Med. 2005
May;2(3):291-300.
14. Brotto LA. Improving the Female Sexual
Function Index. [Letter]. J Sex Marital Ther.
2009;35(2):83-5.
15. Gianotten WL, editor. Seksualiteit bij ziekte
en lichamelijke beperking. Assen: Koninklijke van Gorcum BV; 2008.
16. Bygdeman M, Swahn ML. Replens versus
dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal
women. Maturitas. 1996 Apr;23(3):259-63.
17. Kenemans P, Bundred NJ, Foidart JM,
Kubista E, Schoultz B von, Sismondi P, et al.
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a
double-blind, randomised, non-inferiority
trial. Lancet Oncol. 2009 Feb;10(2):135-46.
NVFB-Bulletin • december 2011 • Nummer 26
1